GSK Is Breathing Easier On Advair Labeling, Expects Sales To Rebound
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline has increased the number of sales reps behind the long-acting beta antagonist to correct "labeling misperceptions."
You may also be interested in...
GSK Submits Advair sNDA Based on TORCH Data
Company is seeking expanded labeling and approval of an increased dosage for treatment of COPD.
GSK Submits Advair sNDA Based on TORCH Data
Company is seeking expanded labeling and approval of an increased dosage for treatment of COPD.
Long-Acting Beta Agonists Revised Labeling Warns Of Asthma Death Potential
FDA issues revised labeling for GlaxoSmithKline’s Serevent, Advair, but continues to negotiate changes to Novartis/Schering’s Foradil.